Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study

Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study

BackgroundCurrently, integrase inhibitors (INIs)-based ART regimens are the preferred initial therapy for AIDS patients. There is scarce information on the use of dolutegravir (DTG) among late-presenter people living with HIV (PLHIV).ObjectivesTo compare the effect of DTG- or efavirenz (EFV)-based r...

Full description

Bibliographic Details
Main Authors:	Carlos Brites, Marcus Lacerda, Eduardo Sprinz, Monica Bay, Gustavo Pinto, Pollyanna Azevedo, Estela Luz, Liliane Lins-Kusterer, Eduardo M. Netto
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Medicine
Subjects:	early mortality advanced AIDS dolutegravir efavirenz adverse (side) effects
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1302710/full

Similar Items

Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir
by: Supphachoke Khemla, et al.
Published: (2023-04-01)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
by: Ayal MA, et al.
Published: (2023-04-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
by: Chang Huang, et al.
Published: (2023-03-01)

Effect of dolutegravir-based versus efavirenz-based antiretroviral therapy on excessive weight gain in adult treatment-naïve HIV patients at Matsanjeni health center, Eswatini: a retrospective cohort study
by: Didier M. Mukuna, et al.
Published: (2024-01-01)

Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries
by: Joel Sim, et al.
Published: (2018-10-01)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
by: John C. Chapola, et al.
Published: (2023-09-01)

Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study
by: Mohammed Jemal, et al.
Published: (2023-12-01)

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context
by: Alana T. Brennan, et al.
Published: (2023-03-01)

Weight gain on dolutegravir: Association is not the same as causation
by: Gary Maartens, et al.
Published: (2023-05-01)

Revisiting efavirenz in the era of dolutegravir: Low-dose efavirenz, a viable alternative capable of holding its own against dolutegravir-based regimens
by: Sumit Arora, et al.
Published: (2023-01-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
by: Aprilianti S, et al.
Published: (2024-01-01)

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
by: Mingli Zhong, et al.
Published: (2023-01-01)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
by: Gabriella Jomara da Silva, et al.
Published: (2023-05-01)

Perspectives of healthcare professionals of the neuropsychiatric side effects associated with efavirenz and its management
by: Razia Gaida, et al.
Published: (2018-10-01)

Two cases of neural tube defects with dolutegravir use at conception in south Brazil
by: Regis Kreitchmann, et al.
Published: (2021-03-01)

Efavirenz and neuropsychiatric effects
by: Mukesh Dheda
Published: (2017-04-01)

Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up
by: Érico C. Cardoso-Neto, et al.
Published: (2023-09-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
by: Adelline Twimukye, et al.
Published: (2021-11-01)

Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape
by: Razia Gaida, et al.
Published: (2016-06-01)

Influence of milling process on efavirenz solubility
by: Erizal Zaini, et al.
Published: (2017-01-01)

Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells
by: Joseph W. George, et al.
Published: (2021-05-01)

A Case Series of Efavirenz Induced Gynaecomastia
by: Charu Jain , Neha Sharma , Uma Advani , Lokendra Sharma , Munesh Kumar , Monica Jain
Published: (2023-08-01)

Suicidal overdose of dolutegravir: A case report
by: Rahul Daimari, et al.
Published: (2018-06-01)

Pharmacovigilance of antiretroviral dolutegravir in the state of Paraná
by: Bárbara Thaís Poliselo de Sá, et al.
Published: (2022-01-01)

Body weight and blood pressure changes on dolutegravir‐, efavirenz‐ or atazanavir‐based antiretroviral therapy in Zimbabwe: a longitudinal study
by: Tinei Shamu, et al.
Published: (2024-02-01)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
by: Omobola Yetunde Ojo, et al.
Published: (2023-12-01)

Safety, strength and simplicity of efavirenz in pregnancy
by: Prinitha Pillay, et al.
Published: (2012-03-01)

Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen
by: Ahmed Badat, et al.
Published: (2022-03-01)

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
by: Arturo Ciccullo, et al.
Published: (2022-01-01)

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
by: Perez Nicholas Ochanda, et al.
Published: (2022-06-01)

Como pesquisar o perfil patentário de um fármaco: o caso Efavirenz How to determine the patent profile of a drug: a case study of Efavirenz
by: Jaqueline Mendes Soares, et al.
Published: (2010-01-01)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
by: Selemani Saidi Sungi, et al.
Published: (2018-10-01)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
by: Manoranjenni Chetty, et al.
Published: (2018-03-01)

Efavirenz: History, Development and Future
by: Bárbara Costa, et al.
Published: (2022-12-01)

Efavirenz challenge in patients with nevirapine induced Stevens-Johnson Syndrome
by: Thandekile C. Manzini, et al.
Published: (2016-12-01)

Careful consideration when responding to new data: dolutegravir and pregnancy
by: C. Foster, et al.
Published: (2018-07-01)

Monitoring plasmatic concentrations of efavirenz for prediction of clinical outcomes in people living with HIV
by: Thaís Lorenna Souza Sales, et al.
Published: (2022-04-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)